Evidence map›Paper›PMID 33130568›Full record

ArticleBMJ open2020

Utilisation and outcomes of allogeneic hematopoietic cell transplantation in Ontario, Canada, and New York State, USA: a population-based retrospective cohort study.

Samantha Aliza Hershenfeld, John Matelski, Vicki Ling, Michael Paterson, Matthew Cheung, Peter Cram

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Increasing access to allogeneic hematopoietic cell transplant: an international perspective.Hematology. American Society of Hematology. Education Program · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

Samantha Aliza HershenfeldFaculty of Medicine, University of Toronto, Toronto, Ontario, Canada.ORCID 0000-0002-6978-1816
John MatelskiDivision of General Internal Medicine and Geriatrics, Sinai Health System and University Health Network, Toronto, Ontario, Canada.
Vicki LingInstitute for Clinical Evaluative Sciences (ICES), Toronto, Ontario, Canada.
Michael PatersonInstitute for Clinical Evaluative Sciences (ICES), Toronto, Ontario, Canada.
Matthew CheungFaculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
Peter CramFaculty of Medicine, University of Toronto, Toronto, Ontario, Canada peter.cram@uhn.ca.ORCID 0000-0002-1910-346X
Institute for Clinical Evaluative Sciences · CAUniversity Health Network · CASunnybrook Health Science Centre · CAUniversity of Toronto · CA

Funding

Comparing hospitalization rates, outcomes, and treatment intensity for elderly patients across OECD countriesR01AG058878 · NIA · HARVARD MEDICAL SCHOOL · PI Peter M Cram, Bruce E. Landon · 2019 to 2026
$3.4M
NIA NIH HHS R01 AG058878
6 · The paper itself

Abstract

objectiveAllogeneic haematopoietic cell transplantation (HCT) is a potentially curative treatment for haematologic and oncologic diseases. There is a perception that the United States of America (USA) offers greater access to expensive therapies such as HCT. Alternatively, Canada is thought to suffer from protracted wait times, but lower spending. Our objective was to compare HCT utilisation and short-term outcomes in Ontario (ON), Canada, and New York State (NY), USA. DESIGN, SETTING AND

participantsWe conducted a population-based cohort study using administrative health data to identify all residents of ON and NY who underwent allogeneic HCT between 2012 and 2015. PRIMARY AND SECONDARY OUTCOME MEASURES: The primary outcome measures were age and sex standardised HCT utilisation rates, in-hospital mortality, hospital length of stay (LOS) and readmission rates in ON and NY. Secondary outcomes included comparing ON and NY HCT recipients with respect to demographic characteristics and patient wealth (using neighbourhood income quintile).

resultsWe identified 547 HCT procedures in ON and 1361 HCT procedures performed in NY. HCT recipients in ON were younger than NY (mean age 49.0 vs 51.6 years; p<0.001) and a lower percentage of ON recipients resided in affluent neighbourhoods compared with NY (47.2% vs 52.6%; p=0.026). Utilisation of HCT was 14.4 per 1 million population per year in ON and 26.7 per 1 million per year in NY (p<0.001). The magnitude of the ON-NY difference in utilisation was larger for older patients. In-hospital mortality, LOS and readmission rates were lower in ON than NY in both unadjusted and adjusted analyses.

conclusionsWe found significantly lower utilisation of HCT in ON compared with NY, particularly among older patients. Higher in-hospital mortality in NY relative to ON requires further study. These differences are thought provoking for patients, healthcare providers and policy-makers in both jurisdictions.

Indexed as

Hematopoietic Stem Cell TransplantationTransplantation, HomologousCohort StudiesFemaleHealth Services AccessibilityHumansMiddle AgedNew YorkOntarioPatient Acceptance of Health CareRetrospective StudiesUnited Statesbone marrow transplantationhaematologyhealth policyhealth services administration & management

Identifiers

PMID33130568
PMCPMC7783612
OpenAlexW3094857069

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.